The use of monoclonal antibodies for the diagnosis and therapy of bladder cancer.

Abstract

British Journal of UrologyVolume 71, Issue 2 p. 121-129 The Use of Monoclonal Antibodies for the Diagnosis and Therapy of Bladder Cancer PAMELA J. RUSSELL, Corresponding Author PAMELA J. RUSSELL Kanematsu Laboratories and Urological Cancer Research Unit, Royal Prince Alfred Hospital, Camperdown; Department of Surgery, University of Sydney, Sydney, Australia Pamela J. Russell, BSc, MSc, PhD, DipEd, formerly Senior Research Fellow, Kanematsu Laboratories, now Director, Oncology Research Centre, Prince of Wales Hospital, SydneyOncology Research Centre, Villa 1, Prince of Wales Hospital, High Street, Randwick, NSW 2031, Australia.Search for more papers by this authorJANE PLOMLEY, JANE PLOMLEY Kanematsu Laboratories and Urological Cancer Research Unit, Royal Prince Alfred Hospital, Camperdown; Department of Surgery, University of Sydney, Sydney, Australia Jane Plomley, BSc(Hons) student, University of SydneySearch for more papers by this authorD. RAGHAVAN, D. RAGHAVAN Kanematsu Laboratories and Urological Cancer Research Unit, Royal Prince Alfred Hospital, Camperdown; Department of Surgery, University of Sydney, Sydney, Australia D. Raghavan, PhD, FRACP, formerly Staff Oncologist and Director of Urological Cancer Research Unit, Royal Prince Alfred Hospital. Now Chief, Division of Solid Tumor Oncology and Investigational Therapeutics, and Professor, Department of Medicine, Roswell Park Cancer Institute, Buffalo, USASearch for more papers by this author PAMELA J. RUSSELL, Corresponding Author PAMELA J. RUSSELL Kanematsu Laboratories and Urological Cancer Research Unit, Royal Prince Alfred Hospital, Camperdown; Department of Surgery, University of Sydney, Sydney, Australia Pamela J. Russell, BSc, MSc, PhD, DipEd, formerly Senior Research Fellow, Kanematsu Laboratories, now Director, Oncology Research Centre, Prince of Wales Hospital, SydneyOncology Research Centre, Villa 1, Prince of Wales Hospital, High Street, Randwick, NSW 2031, Australia.Search for more papers by this authorJANE PLOMLEY, JANE PLOMLEY Kanematsu Laboratories and Urological Cancer Research Unit, Royal Prince Alfred Hospital, Camperdown; Department of Surgery, University of Sydney, Sydney, Australia Jane Plomley, BSc(Hons) student, University of SydneySearch for more papers by this authorD. RAGHAVAN, D. RAGHAVAN Kanematsu Laboratories and Urological Cancer Research Unit, Royal Prince Alfred Hospital, Camperdown; Department of Surgery, University of Sydney, Sydney, Australia D. Raghavan, PhD, FRACP, formerly Staff Oncologist and Director of Urological Cancer Research Unit, Royal Prince Alfred Hospital. Now Chief, Division of Solid Tumor Oncology and Investigational Therapeutics, and Professor, Department of Medicine, Roswell Park Cancer Institute, Buffalo, USASearch for more papers by this author First published: February 1993 https://doi.org/10.1111/j.1464-410X.1993.tb15903.xCitations: 8 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Citing Literature Volume71, Issue2February 1993Pages 121-129 RelatedInformation